Patents by Inventor Hye Jung Baik

Hye Jung Baik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sustained-release lipid pre-concentrate of GNRH analogues and pharmaceutical composition comprising the same
    Patent number: 10722585
    Abstract: Disclosed is a pharmaceutical composition, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) at least one phospholipid; c) at least one liquid crystal hardener which is free of an ionizable group and has a triacyl group with 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety; and d) at least one GnRH (gonadotropin-releasing hormone) analogue as a pharmacologically active substance, wherein said lipid pre-concentrate exists as a liquid phase in absence of aqueous fluid and forms into a liquid crystal in presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active substance GnRH analogue.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: July 28, 2020
    Assignee: Chong Kun Dang Pharmaceutical Corp.
    Inventors: Sang Phil Yoon, Ki Seong Ko, Ha Na Yu, Hye Jung Baik, Won Kyu Yang, Jin Young Ko, So Hyun Park, Sung Bum Jung, Sung Won An, Min Hyo Ki
  • SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF GNRH ANALOGUES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    Publication number: 20150297726
    Abstract: Disclosed is a pharmaceutical composition, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) at least one phospholipid; c) at least one liquid crystal hardener which is free of an ionizable group and has a triacyl group with 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety; and d) at least one GnRH (gonadotropin-releasing hormone) analogue as a pharmacologically active substance, wherein said lipid pre-concentrate exists as a liquid phase in absence of aqueous fluid and forms into a liquid crystal in presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active substance GnRH analogue.
    Type: Application
    Filed: December 27, 2013
    Publication date: October 22, 2015
    Inventors: Sang Phil Yoon, Ki Seong Ko, Ha Na Yu, Hye Jung Baik, Won Kyu Yang, Jin Young Ko, So Hyun Park, Sung Bum Jung, Sung Won An, Min Hyo Ki
  • SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF CATIONIC PHARMACOLOGICALLY ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    Publication number: 20150265535
    Abstract: Disclosed is a sustained-release lipid pre-concentrate, comprising: a) at least one liquid crystal former; b) at least one neutral phospholipid; c) at least one liquid crystal hardener; and d) at least one anionic anchoring agent, wherein the sustained-release pre-concentrate exists as a lipid liquid phase in the absence of aqueous fluid and forms into a liquid crystal upon exposure to aqueous fluid. The sustained-release lipid pre-concentrate is configured to enhance the sustained release of cationic pharmacologically active substance through ionic interaction between the anionic anchoring agent and the cationic pharmacologically active substance.
    Type: Application
    Filed: December 27, 2013
    Publication date: September 24, 2015
    Inventors: Ha Na Yu, Hye Jung Baik, Won Kyu Yang, Jin Young Ko, Sung Bum Jung, Sung Won An, Min Hyo Ki